Healthcare / Drug Manufacturers - Specialty & GenericOslo
$20.90
-0.10 (-0.48%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $67.1M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$927M
P/E
12.4x
↓EV/EBITDA
7.6x
↓ROE
22.7%
↑Gross Margin
51.3%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.3%
FCF CAGR
—
FCF margin
13.6%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $452.3M · net income $74.8M · FCF $61.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $452.3M | $452.3M | $429.1M | $435.4M | $287.7M |
| Net Income | $74.8M | $74.8M | $62.7M | $45.6M | $-4.7M |
| EBITDA | $120.3M | $120.3M | $101.8M | $78.1M | $8.4M |
| EPS | 1.69 | 1.69 | 1.42 | 1.03 | -0.11 |
| Gross Margin | 51.3% | 51.3% | 50.0% | 45.2% | 30.5% |
| Operating Margin | 20.4% | 20.4% | 19.9% | 15.8% | -2.1% |
| Net Margin | 16.5% | 16.5% | 14.6% | 10.5% | -1.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.18 |
| Current Ratio | 2.96 | 2.96 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $61.4M | $61.4M | $67.1M | $72.7M | $-74.8M |
| Returns | |||||
| ROE | 22.7% | 22.7% | 20.3% | 14.1% | -1.7% |
| Valuation | |||||
| P/E | 12.44 | 12.44 | 16.48 | 22.82 | — |
| EV/EBITDA | 7.57 | 7.57 | 10.08 | 13.03 | 90.16 |
| P/B | 2.82 | 2.82 | 3.35 | 3.23 | 2.60 |
| Growth & Yield | |||||
| Revenue Growth | 5.4% | 5.4% | -1.4% | 51.3% | — |
| EPS Growth | 19.0% | 19.0% | 37.9% | 1036.4% | — |
| Dividend Yield | 10.7% | 10.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
3.1%
EPS terminal req.
$1.85
Spread vs growth
15.9%
5Y implied EPS CAGR
5.8%
EPS terminal req.
$2.24
Spread vs growth
13.2%
10Y implied EPS CAGR
7.9%
EPS terminal req.
$3.61
Spread vs growth
11.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.0%
Start / end P/E
17.7x → 12.4x
EPS bridge
1.42 → 1.69
Residual
-5.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.